Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 hospitalized meta-analysis

Elgazzar - treatment, 2020 RCTivermectinhydroxychloroquineCOVID 19 hospitalizedhigh
200/200 suggested
  • suggested 93 % decrease in deaths but with a low degree of certainty due to high risk of bias
Gonzalez_IVER, 2020
 
NCT04391127
RCTivermectinplaceboCOVID 19 hospitalizedsome concern
36/37 inconclusive
    ICON, 2020 OBSivermectinstandard of careCOVID 19 hospitalizedNA
    173/107 suggested
    • suggested 53 % decrease in deaths (PE)
    Khan, 2020 OBSivermectinstandard of careCOVID 19 hospitalized, COVID-19 mild to moderateNA
    115/133 suggested
    • suggested 88 % decrease in deaths
    • suggested 7.3-fold increase in clinical improvement
    • suggested 88 % decrease in ventilation

    COVID-19 mild to moderate meta-analysis

    Babalola, 2021 RCTivermectinlopinavir/ritonavirCOVID-19 mild to moderatehigh
    21/20 no results
      Bukhari, 2021
       
      NCT04392713
      RCTivermectinstandard of careCOVID-19 mild to moderatehigh
      50/50 suggested
      • suggested 10.6-fold increase in viral clearance by day 7 but with a low degree of certainty due to high risk of bias
      Kirti, 2021
       
      CTRI/2020/08/027225
      RCTivermectinplaceboCOVID-19 mild to moderatesome concern
      57/58 inconclusive
      • inconclusive 20 % decrease in viral clearance by day 7 (PE) with a moderate degree of certainty due to some concern in risk of bias
      RIVET-COV (Mohan), 2021
       
      CTRI/2020/06/026001
      RCTivermectinplaceboCOVID-19 mild to moderatehigh
      100/52 inconclusive
        Ahmed, 2020 RCTivermectinplaceboCOVID-19 mild to moderatehigh
        48/24 suggested
        • suggested 3.1-fold increase in viral clearance (time to event analysis only),viral clearance by day 14 (PE) but with a low degree of certainty due to high risk of bias
        Paradoxically comparison of day 7 and 14 virological clearance between ivermectin doxycycline group vs placebo was not statistically significant (HR 2.3[0.6-9.0] and 1.7[0.8-4.0])
        Chaccour, 2020
         
        NCT04390022
        RCTivermectinplaceboCOVID 19 outpatients, COVID-19 mild to moderatelow
        12/12 inconclusive
        • inconclusive 8 % decrease in viral clearance ,viral clearance by day 7 (PE) with a high degree of certainty due to low risk of bias
        Chachar, 2020
         
        NCT04739410
        RCTivermectinstandard of careCOVID-19 mild to moderatehigh
        25/25 inconclusive
        • inconclusive 19 % increase in clinical improvement,clinical improvement (7-day) (PE) but with a low degree of certainty due to high risk of bias
        Krolewiecki, A, 2020
         
        NCT04381884
        RCTivermectinstandard of careCOVID-19 mild to moderatesome concern
        30/15 inconclusive
          Viral load reduction between baseline and day-5 was also similar between groups
          Glorial F, 2020
           
          NCT04343092
          OBSivermectinstandard of careCOVID-19 mild to moderateNA
          6/71 inconclusive
          • inconclusive 10 % decrease in clinical improvement (PE)
          Soto-Becerra, 2020 OBSivermectinstandard of careCOVID 19 hospitalized, COVID-19 mild to moderatemoderate
          203/2630 safety concern
          • inconclusive 39 % increase in deaths,deaths (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
          • statistically significant 58 % increase in death or transfer to ICU with a moderate degree of certainty due to some concern in risk of bias
          Our study reported no beneficial effects of hydroxychloroquine, ivermectin, azithromycin. The HCQ AZIT treatment seems to increase risk for all-cause death
          Espitia-Hernandez, 2020 NRaivermectinstandard of careCOVID 19 outpatients, COVID-19 mild to moderateNA
          28/7 suggested
          • suggested 714.0-fold increase in viral clearance
          Spoorthi, 2020 NRaivermectinplaceboCOVID 19 hospitalized, COVID-19 mild to moderateNA
          50/50 inconclusive

            COVID-19 severe or critically meta-analysis

            Galan, 2021
             
            RBR-8h7q82
            RCTivermectinchloroquine and derivativesCOVID-19 severe or criticallysome concern
            53/115 suggested
            • inconclusive 6 % decrease in deaths (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
            • suggested 86 % decrease in ventilation with a moderate degree of certainty due to some concern in risk of bias
            Galan, 2021
             
            RBR-8h7q82
            RCTivermectinhydroxychloroquineCOVID-19 severe or criticallysome concern
            53/115 suggested
            • inconclusive 6 % decrease in deaths (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
            • suggested 86 % decrease in ventilation with a moderate degree of certainty due to some concern in risk of bias
            Niaee (vs placebo), 2020
             
            IRCT20200408046987N1
            RCTivermectincontrolCOVID-19 severe or criticallyhigh
            120/30 suggested
            • suggested 86 % decrease in deaths but with a low degree of certainty due to high risk of bias
            Okumuş, 2020
             
            NCT04646109
            RCTivermectincontrolCOVID-19 severe or criticallyhigh
            30/30 inconclusive
              Camprubi, 2020 OBSivermectinstandard of careCOVID-19 severe or criticallyNA
              13/13 inconclusive

                COVID 19 outpatients meta-analysis

                Lopez-Medina, 2021
                 
                NCT04405843
                RCTivermectinplaceboCOVID 19 outpatientssome concern
                200/200 inconclusive
                • inconclusive 7 % increase in clinical improvement,clinical improvement (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
                Podder, 2020 RCTivermectinstandard of careCOVID 19 outpatientshigh
                32/30 inconclusive

                  PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
                  Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).